Cereno Scientific obtains patents in 15 European countries solidifying CS1’s protection
Cereno Scientific (XSAT: CRNO B) today announced that CS1’s first patent family has been granted patents in 15 European countries following a completed validation and opposition period. This adds to the already granted markets that include Australia, Canada, Japan, and the US, thus securing patent protection for CS1 in nearly all global key markets.
“It is great to obtain our first patent for CS1 in Europe. Adding this market to the already granted markets offers a good broad patent protection, which is generally an important factor when looking at an asset’s commercial potential,” said Sten R. Sörensen, CEO at Cereno Scientific.
The granted European patent of Cereno’s first patent family, related to drug candidate CS1, is titled "Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors”, EP2683371. The European Patent Office (EPO) first conducted a coordinated search and evaluation on behalf of all member countries; following a positive response and subsequent patent issuance, Cereno selected the 15 key strategic markets in Europe to complete the registration of individual national patents in these markets.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.